NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Bone Cancer. They are currently available as Version 2.2010.
A new page entitled Bone Cancer Systemic Therapy Agents has been added. This page includes specific recommendations for common systemic therapy agents/regimens for bone cancers.
NCCN has published updates to the NCCN Guidelines for Colon Cancer and the NCCN Guidelines for Rectal Cancer. They are both currently available as Version 2.2010.
In both the NCCN Guidelines™ for Colon Cancer and the NCCN Guidelines™ for Rectal Cancer, panitumumab was added as an alternate option to cetuximab in combination therapies with FOLFOX and FOLFIRI for patients with advanced or metastatic disease. Also, cetuximab was removed from combination therapies with capecitabine and oxaliplatin in the advanced or metastatic setting. FOLFIRI + panitumumab was added as a second-line treatment option for patients progressing on FOLFOX ± bevacizumab. The category 2B recommendation was changed to category 2A for FOLFIRI + cetuximab in second-line therapy.
NCCN Drugs & Biologics Compendium (NCCN Compendium™) chapters for Multiple Myeloma and Prostate Cancer were also updated. The NCCN Compendium™ for Multiple Myeloma is now Version 3.2010 and the NCCN Compendium for Prostate Cancer is now Version 1.2010.